Рокситромицин

Quick links

Choose a section

Quick links to important sections

Advertisements

Рокситромицин

Advertisements
Advertisements

Overview of Рокситромицин

Quick Facts

Property Description
Active ingredient Roxithromycin
Form Tablets, Oral Suspension (Oral Administration)
Pharmacological class Macrolide Antibiotic (Anti-infective agent)
Common purpose To inhibit the growth of susceptible bacteria
Origin Semisynthetic derivative of Erythromycin

Что такое Рокситромицин: Класс и Происхождение (What is Roxithromycin: Class and Origin)

Рокситромицин is a single-ingredient medication, formally recognized by the INN Roxithromycin, which functions as an anti-infective agent. It belongs to the macrolide antibiotic pharmacological class, designated by the WHO Anatomical Therapeutic Chemical Code system. The compound is a semisynthetic derivative created from the core structure of Erythromycin to enhance its pharmaceutical properties.

This structural modification provides the molecule with increased stability and improved absorption for its intended oral administration. The medication is typically supplied in tablets or an oral suspension and is clinically recognized under various brand names, such as Rulide.

Рокситромицин: Механизм и Назначение (Mechanism and Purpose)

Рокситромицин is an established antibiotic with the general purpose of controlling the spread of bacterial infections. Its primary physiological action is bacteriostatic, meaning it works by halting the growth and reproduction of susceptible bacteria rather than immediately destroying them.

The medication achieves this by entering the bacterial cell and interfering with its internal protein synthesis. It does this by binding specifically to the bacteria's 50S ribosomal subunit, which blocks the assembly of essential proteins needed for cell replication. Pharmacological studies support that this targeted mechanism allows the drug to effectively arrest bacterial proliferation, which is useful in treating infections. This action allows the host’s immune system sufficient time to successfully neutralize and remove the static bacterial population.

Улучшенные Свойства (Improved Properties)

Рокситромицин was developed to address limitations present in its predecessor, Erythromycin. The resulting semisynthetic structure provides a more favorable pharmacokinetic profile, which includes increased resistance to stomach acid and a significantly longer half-life (approximately 10–12 hours) compared to the original compound. This extended half-life often translates into a simpler, less frequent dosing schedule, which is a key feature that enhances patient convenience and adherence to the treatment regimen.

Advertisements

What side effects are possible with Рокситромицин?

Possible Side Effects and Safety Information

The official safety documentation for Roxithromycin, a macrolide antibiotic, defines its risk profile through frequency classifications and specific system-organ categories, as reported to regulatory authorities (EMA, FDA, etc.). This information is strictly descriptive and non-advisory.


Adverse Reaction Classifications

Adverse effects are documented according to their frequency and the physiological systems affected:

Classification (Frequency) Associated System-Organ Classes (SOC) Examples of Documented Effects
Common (1/100) Gastrointestinal, Nervous System Nausea, vomiting, diarrhea, headache, dizziness
Uncommon (1/1,000) Immune System, Skin Rash, urticaria
Frequency Unknown Cardiac, Hepatobiliary, Psychiatric QT prolongation, Torsades de pointes, cholestatic hepatitis, hallucinations

Clinically Significant and Serious Reactions

The regulatory profile highlights rare but serious adverse reactions, including severe hypersensitivity events such as anaphylactic shock and serious cutaneous reactions like Stevens-Johnson Syndrome. A significant safety concern is the potential for prolongation of the QT interval, which carries a risk of life-threatening ventricular arrhythmias.

Safety Constraints and Considerations

Specific safety constraints are mandated in the official labeling. Roxithromycin is not recommended in patients with severe hepatic impairment. Caution is required in individuals with pre-existing conditions that increase the risk of QT prolongation, including concurrent use of other QT-prolonging medicinal products. Furthermore, the risk of Clostridium difficile-associated diarrhea may extend to several weeks after the end of treatment.

Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help

The information in this section is derived strictly from official government regulatory documents and prescribing information. Any suspected overdose with Roxithromycin requires immediate professional medical attention.

Documented Overdose Manifestations

Official labeling indicates that overdose may manifest as an amplification of common gastrointestinal disturbances, including nausea, vomiting, and diarrhea. Central Nervous System effects, such as headache and dizziness, may also occur. Acute toxicity is generally considered low; however, the experience of severe overdose is limited.

System Potential Manifestation
Gastrointestinal Nausea, Vomiting, Diarrhea
Cardiovascular Risk QT Interval Prolongation, Torsade de Pointes

Mandatory Emergency Actions

In the event of suspected overdose, immediate medical attention must be sought. It is required to contact a doctor, Poison Control Center, or go to the nearest Emergency Department. This action is mandated by regulators even if there are no immediate signs of discomfort or poisoning.

Management and Specific Considerations

Treatment for Roxithromycin overdose is symptomatic and supportive, as no specific antidote is known. Officially recognized procedural steps for management may involve gastric lavage and the use of activated charcoal. A specific consideration exists for patients with severe hepatic impairment, as their prolonged serum half-life increases susceptibility to toxicity, indicating a risk factor for overdose complications.

Advertisements

Therapeutic Uses of Рокситромицин

Рокситромицин: Основные Области Применения и Польза

Рокситромицин (Roxithromycin) is commonly used in clinical settings that involve acute or unstable symptom patterns associated with susceptible bacterial infections. The medication is applied across domains where additional symptomatic support is needed, including infections of the upper and lower respiratory tract (such as pharyngitis and acute bronchitis), skin and soft tissues (like impetigo and cellulitis), and specific genitourinary tract infections (such as non-gonococcal urethritis).

The medication is used for managing symptoms that create noticeable physiological strain, like significant fever, localized pain, and inflammation. The treatment contributes to easing the overall symptom load and helps maintain a sense of stability during symptomatic periods.

“The medication is applied across domains where additional symptomatic support is needed in conditions where acute infection is causing heightened patient discomfort.”

Quick Fact: Management of Acute Symptoms

Condition Category Symptom Cluster Managed Support Provided
Acute Infections Pain, fever, and inflammation Assists with maintaining functional stability
Advertisements

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Roxithromycin — Official Regulatory Information

The eligibility profile for Roxithromycin, a macrolide antibiotic, is strictly defined by regulatory documents, distinguishing between populations that are permitted use, restricted, or absolutely contraindicated.

Contraindicated Populations (Absolute Non-Eligibility)

Use is strictly contraindicated for individuals with a known hypersensitivity to macrolide antibiotics or Roxithromycin itself. Non-eligibility also applies to patients with severely impaired hepatic function or specific pre-existing cardiac conditions such as a history of congenital long QT syndrome. Furthermore, the medicine must not be used concurrently with certain QT-prolonging drugs (e.g., cisapride) or vasoconstrictive ergot alkaloids.

Age and Condition-Based Restrictions

Age-related eligibility rules typically permit use in adults and older adults. For children, eligibility is often dependent on a minimum threshold, with tablets not recommended for those weighing less than 40 kg or under six years of age. Use is not recommended for pregnant or breastfeeding patients as the drug is excreted into breast milk and requires a formal risk-benefit assessment by a healthcare professional. Patients with mild to moderate hepatic impairment are restricted to conditional use and may require a dosage adjustment.

Advertisements

What should I know about interactions with other medicines?

Roxithromycin Interactions with Other Medicines and Products

Roxithromycin's official interaction profile is defined by its documented effect as a weak inhibitor of the CYP3A4 isoenzyme and its potential to contribute to cardiovascular risk.

Contraindicated Combinations

Co-administration with vasoconstrictive ergot alkaloids (e.g., Ergotamine, Dihydroergotamine) is strictly contraindicated due to the risk of severe vasoconstriction. The simultaneous use of Roxithromycin with specific QT-prolonging CYP3A4 substrates, such as Astemizole, Cisapride, Pimozide, and Terfenadine, is also contraindicated due to the risk of severe ventricular arrhythmias.


Clinically Significant Interactions

Interacting Substance Regulatory Outcome Constraint / Requirement
Vitamin K Antagonists (e.g., Warfarin) Increased International Normalised Ratio (INR) reported. Requires strict monitoring of INR due to bleeding risk.
Digoxin Increased absorption and plasma concentration documented. Requires monitoring of serum levels and ECG.
Food Intake Oral absorption is officially decreased. Tablets must be taken on an empty stomach (e.g., before eating) to ensure optimal absorption.
Severe Hepatic Impairment Altered pharmacokinetics; safety not demonstrated. Consideration may be given to reducing the daily dosage by half.

Co-administration with other drugs known to prolong the QT interval (e.g., Class IA and III antiarrhythmics) requires caution due to potential additive cardiotoxicity. Roxithromycin is also documented to increase the plasma levels of CYP3A4 substrates, including Midazolam, Ciclosporine, and Theophylline.

Advertisements

Mechanism of Action

Targeted Blockade of Bacterial Protein Synthesis

This domain describes Roxithromycin's central mechanism of action: acting as a highly specific inhibitor by binding to the 50S ribosomal subunit inside susceptible bacteria. This targeted action physically obstructs the process of peptide chain elongation, thereby preventing the synthesis of essential structural and enzymatic proteins.


Arrest of Bacterial Proliferation (Bacteriostasis)

The immediate physiological consequence of inhibiting protein synthesis is to arrest the bacteria's ability to divide and grow, resulting in a state of bacteriostasis. This mechanism causes a cessation of bacterial proliferation, which results in a static microbial load. The resulting bacteriostasis establishes a dependency on the host's immune system for the clearance of the non-replicating microbial population.


️ Mechanistic Constraint: Failure due to Target Modification

The drug's core mechanism is constrained by bacterial countermeasures, specifically the ability to modify the 50S ribosomal subunit (e.g., rRNA methylation). This target modification critically reduces Roxithromycin's binding affinity, functionally nullifying the ribosomal blockade and preventing the necessary bacteriostatic effect, a state recognized as acquired macrolide resistance.

Advertisements

Dosage and Administration Information

How to Use Roxithromycin

The usage of Roxithromycin (Рокситромицин) is standardized around the oral route of administration, typically via 150 mg or 300 mg film-coated tablets. The core principle of its administration is adherence to an empty stomach condition to ensure optimal absorption. It is generally required for the medicine to be taken at least 15 minutes before a meal or more than 3 hours after a meal. The tablets must be swallowed whole with a drink and are not to be crushed or chewed.

Standard Dosage and Frequency

For adults and adolescents weighing 40 kg or more, the standard total daily dose is 300 mg. This dosage can be fulfilled either by taking one 300 mg tablet once daily (o.d.) or by dividing the amount into 150 mg doses twice daily (b.i.d.). Pediatric patients below 40 kg are typically dosed by body weight at 5 to 8 mg/kg/day in two divided administrations.

Course Duration and Adjustments

The total treatment course typically lasts 5 to 10 days. For specific infections, such as those caused by beta-haemolytic streptococci, a minimum duration of 10 days is required. Dosage adjustments are applied for certain patient groups. Individuals with severe hepatic impairment (e.g., cirrhotic liver disease) must reduce their dose by half to 150 mg once daily. Conversely, no dosage adjustment is typically necessary for elderly patients or those with impaired renal function.

Advertisements

Recent Clinical Evidence

Research Evidence: Overview of Roxithromycin Studies


Studies in Acute Respiratory Infections

Research on Roxithromycin for acute infections like bronchitis, tonsillitis, pharyngitis, and certain types of mild pneumonia primarily involves short-term Randomized Controlled Trials (RCTs) and systematic reviews. These studies examined adult patients with episodic or acute symptoms, monitoring key outcomes including the measurement of changes in physical discomfort and systemic signs, as well as the monitoring of bacteriological eradication. In comparative trials, patterns in clinical and bacteriological measurements were reported across the groups studied. However, follow-up durations were often limited, and information on long-term outcomes is scarce.


Overview of Skin and Soft Tissue Infection Studies

Roxithromycin was studied for conditions involving the skin and soft tissues, such as impetigo and cellulitis. The main body of research includes RCTs designed to compare Roxithromycin with other antibiotics. Studies explored outcomes related to physical discomfort and inflammation, observing how signs of infection evolved in populations including both adults and children. Evidence quality varies across studies, and there is limited recent information from very large-scale trials. Data for certain subgroups, particularly those with underlying health issues that complicate healing, remain insufficient.


Key Gaps and Uncertainties in Research

Several limitations are noted in the overall research landscape. Most significantly, there is limited information for long-term outcomes across all licensed indications, meaning the follow-up durations were primarily short-term assessments. Evidence for older adults or populations with significant underlying health issues remains less established than for the general trial population. Furthermore, many core trials are older, and comparative evidence against more recently developed antibiotics is often lacking. Study results reflect the specific conditions under which they were conducted and do not determine whether an individual will respond similarly.

Key Studies & References

  1. WHO Collaborating Centre for Drug Statistics Methodology: ATC/DDD Index J01FA06 (Roxithromycin)
  2. Guidelines for the management of community-acquired pneumonia in adults (Supporting evidence for RTI claim)
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Рокситромицин (FAQ)


Q: What is Рокситромицин primarily used to treat?

Рокситромицин is officially indicated for treating a range of infections caused by susceptible bacteria. These include infections of the lower respiratory tract, like certain pneumonias, as well as acute ear infections (otitis media), and specific skin and soft tissue infections. Official documents also list certain non-gonococcal urogenital infections as approved uses.


Q: What are the main types of bacterial infections for which Рокситромицин is commonly prescribed?

This medicine is typically prescribed for infections such as acute pharyngitis (sore throat), middle ear infections, and certain community-acquired pneumonias. It also targets specific bacterial pathogens like Chlamydia that cause urogenital infections. This usage aligns with the official product information for the drug.


Q: Does Рокситромицин treat viral infections, such as the common cold or flu?

No, Рокситромицин is an antibiotic and its mechanism is to stop the growth and reproduction of bacteria. According to regulatory product information, it has no effect on infections caused by viruses, such as the common cold or influenza (flu).


Q: How does the mechanism of action of Рокситромицин differ from penicillin-type antibiotics?

Рокситромицин belongs to the macrolide class of antibiotics, which work by interfering with the bacteria’s ability to build essential proteins. It is indicated as an alternative treatment when patients cannot use beta-lactam antibiotics (the class that includes penicillin), often due to hypersensitivity or resistance.


Q: Can Рокситромицин cause a fungal infection, like thrush, in the mouth or genital area?

Official product information indicates that the use of this antibiotic may sometimes allow fungi or yeast to overgrow in the body. This can potentially lead to a secondary infection, such as oral thrush in the mouth or vaginal thrush in the genital area.


Q: What signs of an allergic reaction to Рокситромицин should users be aware of?

Regulatory documents describe serious allergic reactions, which may involve swelling of the face, lips, mouth, or throat, potentially causing difficulty with breathing or swallowing. Other serious signs can include severe itchy skin, rash, or the onset of asthma-like symptoms.


Q: What is the general recommendation regarding alcohol consumption while taking Рокситромицин?

While regulatory documents may not specifically list an interaction with alcohol, the medicine is associated with common side effects such as dizziness. Official guidance suggests that consuming alcohol may worsen or contribute to the effects on the central nervous system, such as dizziness or light-headedness.


Q: Is it necessary to use alternative contraception while taking Рокситромицин and the birth control pill?

Most official guidance indicates that broad-spectrum antibiotics, including macrolides like Рокситромицин, are not thought to reduce the efficacy of combined oral contraceptives. However, due to the complexity of hormonal medicines, regulatory bodies advise seeking professional guidance on any concurrent medication use.


Q: How long does Рокситромицин remain in the system after the final dose?

The medicine's half-life—the time it takes for half of the drug to be eliminated—is approximately 10 to 12 hours. Pharmacological principles suggest a drug is almost entirely cleared from the body after about four to five half-lives.


Q: What happens if a dose of Рокситромицин is missed?

Official guidance on a missed dose describes taking the dose as soon as it is remembered. However, if the time for the next scheduled dose is near, the official instruction is for the missed dose to be skipped entirely. Product information consistently notes that taking a double dose is to be strictly avoided.


Q: Is Рокситромицин effective for treating ear infections (otitis media)?

Yes, the official therapeutic indications for Рокситромицин include the treatment of Acute Otitis Media (a common middle ear infection). This application is based on the drug's effectiveness against the susceptible bacteria that cause this condition.


Q: Is Рокситромицин generally considered a broad-spectrum or narrow-spectrum antibiotic?

Рокситромицин is generally described as a macrolide antibiotic with a broad spectrum of activity. This means it is effective against a wide range of susceptible bacteria, including both Gram-positive organisms and some Gram-negative and atypical bacteria.


Q: Can Рокситромицин be used to treat infections that are resistant to penicillin?

Official indications for Рокситромицин allow its use as an alternative for infections where beta-lactam antibiotics, such as penicillin, cannot be used. This may be due to an allergy to penicillin or in cases where the bacteria have developed resistance to that drug class.


Q: Can Рокситромицин cause dizziness, and what precautions are advised?

Dizziness is officially listed as a common side effect of this medicine. Regulatory product information notes that, if dizziness or light-headedness occurs, caution is required regarding activities such as driving or operating machinery.


Q: Can the use of Рокситромицин contribute to antibiotic resistance?

Yes, the use of any broad-spectrum antibiotic, including Рокситромицин, is associated with a risk of contributing to antimicrobial resistance (AMR). Official risk management guidance highlights the need to minimize this risk due to the potential for bacteria to develop resistance to the macrolide class.


Q: Is Рокситромицин effective against infections caused by Chlamydia?

Yes, official product information indicates that Рокситромицин is a recognized treatment for non-gonococcal urogenital infections. This specifically includes infections caused by the bacterium Chlamydia.


Q: Are there any required monitoring tests, such as liver function, for patients on a prolonged course of Рокситромицин?

Official warnings require caution for patients with impaired hepatic (liver) function. If the medicine must be administered in such cases, regulatory documents advise that liver function tests should be regularly monitored during treatment.


Q: Does Рокситромицин have any known interaction with antacids containing aluminum or magnesium?

Based on official studies, the absorption and availability of Рокситромицин in the body are not significantly affected by taking it concurrently with antacids that contain aluminum or magnesium hydroxide.


Q: Is the efficacy of Рокситромицин affected by taking it for less than the full prescribed duration?

Regulatory patient information requires that the full prescribed duration of the medication be completed. Discontinuing treatment early risks incomplete eradication, meaning not all bacteria may be killed, which could allow the infection to return or worsen, as described in official documents.

Advertisements

How should Рокситромицин be stored and disposed of?

Official Storage and Disposal Requirements

Official regulatory documents specify mandatory conditions for storing roxithromycin to maintain product integrity and stability. The medicine must be stored at a controlled temperature, typically below 25 C (or 30 C depending on the formulation). Storage must protect the tablets from light and moisture, and they should remain in the original blister packaging until use.

Child Safety and Expiration: The product must be kept out of the reach of children at all times. Use of the medicine is prohibited after the expiry date printed on the carton.

Disposal Rules: Official instructions prohibit discarding roxithromycin through household waste or wastewater (e.g., flushing down the toilet or sink). Unused or expired medication must be returned to a pharmacist for proper disposal or managed according to local and national environmental protection regulations, as the substance is classified as potentially toxic to the aquatic environment.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Рокситромицин found in:

A-Z Index: